Agilent Technologies (A) Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer

Go back to Agilent Technologies (A) Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer
Agilent Technologies Inc (NYSE: A) Delayed: 156.31 +2.51 (1.63%)
Previous Close $153.80    52 Week High $48.63 
Open $154.76    52 Week Low $34.15 
Day High $156.39    P/E 72.37 
Day Low $153.95    EPS $2.16 
Volume 1,491,465